^
Association details:
| Biomarker: | EGFR exon 19 deletion + PTEN deletion + PIK3CA overexpression |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) + Piqray (alpelisib) (PIK3CA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells
Published date:
08/08/2023
Excerpt:
...we also used H1975 and H1650 lung cancer cells to evaluate the synergetic effects of gefitinib and BYL719....The H1650 cells were with EGFR Exon19 deletion and PTEN deletion...The over-expression of PIK3CA was also confirmed in H1975 and H1650 cells...In the H1650 cells, gefitinib alone or BYL719 alone did not inhibit the cell proliferation, while the combination of the two drugs significantly reduced the cell proliferation, compared with the control group (Fig. 3C, P < 0.05).
DOI:
https://doi.org/10.1186/s12885-023-11243-0
